echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Eli Lilly's RET inhibitor Retsevmo is approved in the UK for the treatment of advanced lung/thyroid cancer

    Eli Lilly's RET inhibitor Retsevmo is approved in the UK for the treatment of advanced lung/thyroid cancer

    • Last Update: 2021-03-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 11, according to foreign media reports, the British Medicines and Health Products Administration granted Eli Lilly’s Retsevmo a conditional marketing license for the treatment of RET fusion-positive advanced lung cancer and thyroid cancer.


    In particular, the authorization includes Restevmo (Selpercatinib) as the only treatment option for patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who require systemic treatment before receiving immunotherapy and/or platinum-based chemotherapy.


    It also includes adults with advanced RET fusion-positive thyroid cancer who need systemic treatment after Sorafenib/Lenvatinib treatment, and adults with advanced RET-mutant medullary thyroid cancer (MTC) 12 years of age and older who need systemic treatment after treatment.


    The UK Medicines and Healthcare Products Administration’s approval is based on the results of the LIBRETTO-00 Phase I/II trial, a single-arm study of more than 700 patients with RET-driven cancer.


    The preliminary analysis included 105 patients who had previously been treated for non-small cell lung cancer (NSCLC), of which 64% were effective for the treatment, with an average validity period of 17.


    Christie’s NHS Foundation Trust’s oncology consultant Yvonne Summers said: “This is good news for RET-driven cancer patients, because they will soon have a treatment option that directly targets RET changes.


    RET fusion-positive tumors occur in 1-2% of non-small cell lung cancer (NSCLC) patients, and are more common in people under 60 years of age.




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.